30 completed, 16 terminated, 3 active not recruiting, 3 unknown. 34 Phase 2, 13 Phase 1, 7 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Hormone-resistant Prostate Cancer: new trials by email Literature Review of Hormone-resistant Prostate Cancer trials Research Report on Hormone-resistant Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility of a New Technology for Isolating Circulating Tumour Cells Blood sample collection - HER2-positive Metastatic Breast Cancer, Ovarian Cancer | Not applicable | Unknown | Centre Oscar Lambret | 76 | 2020-03-11 | 2021-10-13 |
| Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Durvalumab, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer | Phase 2 | Withdrawn | University of Washington | 2018-05-15 | 2018-01-17 | |
| Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer Laboratory Biomarker Analysis, Quality-of-Life Assessment, Trametinib - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2018-01-30 | 2023-05-01 |
| Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Cabazitaxel, Prednisone - Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma | Phase 2 | Terminated | University of California, Davis | 2 | 2017-12-20 | 2021-01-25 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration - Hormone-Resistant Prostate Cancer, Recurrent Prostate Carcinoma | Completed | Wake Forest University Health Sciences | 61 | 2017-02-22 | 2022-03-10 | |
| Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies Carboplatin, Docetaxel - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Terminated | Seattle Institute for Biomedical and Clinical Research | 2 | 2016-11-01 | 2021-08-05 |
| Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer Ascorbic Acid, Docetaxel, Laboratory Biomarker Analysis - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2016-06-20 | 2023-06-07 |
| Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Terminated | University of Southern California | 7 | 2016-06-14 | 2021-04-05 | |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-06-01 | 2017-04-24 | |
| Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO clinical database - Prostate Cancer, Bone Metastases | Completed | Institut du Cancer de Montpellier - Val d'Aurelle | 67 | 2016-01-01 | 2020-08-18 | |
| Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer carbon-11 acetate, fluorine F 18 sodium fluoride, positron emission tomography - Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer | Not applicable | Withdrawn | University of Washington | 2015-12-01 | 2016-08-31 | |
| Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel Dexamethasone, Enzalutamide, Laboratory Biomarker Analysis - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Not applicable | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 5 | 2015-09-01 | 2018-07-12 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer Pembrolizumab, pTVG-HP Plasmid DNA Vaccine - Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Completed | University of Wisconsin, Madison | 66 | 2015-07-01 | 2023-08-01 |
| NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer Contrast-enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Fluorine F 18 Sodium Fluoride - Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone | Phase 1 | Terminated | Stanford University | 4 | 2015-04-01 | 2017-05-30 |
| Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Laboratory Biomarker Analysis, Sipuleucel-T, Tasquinimod - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 2 | 2015-01-01 | 2023-04-27 |
| Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Terminated | University of Southern California | 24 | 2014-12-23 | 2017-04-17 | |
| Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide Enzalutamide, Laboratory Biomarker Analysis, Pembrolizumab - Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer | Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 58 | 2014-11-18 | 2026-05-14 |
| Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer Selinexor - Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer | Phase 2 | Terminated | University of California, San Francisco | 14 | 2014-09-02 | 2018-06-26 |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer sodium selenite, radiation therapy, laboratory biomarker analysis - Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 1 | Completed | Stanford University | 15 | 2014-07-01 | 2024-05-28 |
Showing 20 of 55. Sign in to see all of them.
Prostatic Neoplasms (49) · Ovarian Neoplasms (4) · Breast Neoplasms (3) · Stomach Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Esophageal Neoplasms (2) · Melanoma (2) · Sarcoma (2) · Triple Negative Breast Neoplasms (2) · Urinary Bladder Neoplasms (2) · Astrocytoma (1) · Bone Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1)
Genital Diseases (52) · Neoplasms (52) · Neoplasms by Site (52) · Urogenital Diseases (52) · Urogenital Neoplasms (52) · Male Urogenital Diseases (50) · Genital Diseases, Male (49) · Genital Neoplasms, Male (49) · Prostatic Diseases (49) · Adnexal Diseases (4) · Breast Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4)
Prednisone (9) · Docetaxel (7) · Abiraterone Acetate (4) · Magnetic Resonance Spectroscopy (4) · enzalutamide (4) · Sirolimus (3) · deltacortene (3) · prednylidene (3) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (2) · Bevacizumab (2) · Dasatinib (2) · Diet Therapy (2) · Immunoglobulin G (2) · Radiation (2) · Radiotherapy (2)
National Cancer Institute (NCI) (12) · University of Southern California (8) · OHSU Knight Cancer Institute (4) · Roswell Park Cancer Institute (4) · Barbara Ann Karmanos Cancer Institute (3) · Stanford University (3) · University of Washington (3) · Mayo Clinic (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Alliance for Clinical Trials in Oncology (1) · Centre Oscar Lambret (1) · City of Hope Medical Center (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Jonsson Comprehensive Cancer Center (1) · Seattle Institute for Biomedical and Clinical Research (1)
United States (51) · Canada (2) · France (2) · Puerto Rico (1)
Jacek Pinski (3) · Evan Yu (2) · Mitchell Gross (2) · Primo Lara (2) · Tomasz Beer (2) · Ulka Vaishampayan (2) · Andrei Iagaru (1) · Bart Frizzell (1) · Channing Paller, MD (1) · Charles Ryan, MD (1) · Christopher Evans (1) · Cy Stein, MD, PhD (1) · Dana Rathkopf (1) · Daniel Renouf (1) · Darcy Spicer, MD (1)
PMID 22341993, PMID 23000088, PMID 23326203, PMID 23652277, PMID 24099865, PMID 24993934, PMID 27084275, PMID 28178640, PMID 29027195, PMID 29476383, PMID 29487219, PMID 29876010, PMID 30682445, PMID 30700328, PMID 32616555, PMID 32850444, PMID 34028627, PMID 34616010, PMID 34749008, PMID 35277461, PMID 35771552, PMID 36996380, PMID 38992025, PMID 39076107, PMID 39663356, PMID 40132910, PMID 41346252, PMID 41378786
P30CA014089 (3), P30CA015704 (3), U10CA031946 (3), N01CM00071 (2), P30CA006973 (2), P30CA014599 (2), P30CA069533 (2), P30CA124435 (2), U01CA062491 (2), U10CA180820 (2), N01CM00032 (1), N01CM00070 (1), N01CM00099 (1), N01CM00100 (1), N01CM17101 (1)